combio - terveydenhuollon biomateriaalit
DESCRIPTION
TRANSCRIPT
Tekes – Focusing on Biomaterial Technology
Ms. Aila Maijanen
Tekes,
National Technology Agency of Finland
Senior Technology Advisor
Tekes
Focusing on biomaterial technology
Human Spare PartsOct 21, 2004 - Brussels
Aila MaijanenNational Technology Agency Tekes
Senior technology advisor
Content:
National Technology Agency Tekes: Mission and Activities
Tekes Technology Programmes
Combio – Commercialisation of BiomaterialsTechnology Programme
Conclusion
Public sector activities of R&D in Finland
Ministry ofTrade andIndustry
DM 32190 04-2003 Copyright © Tekes
Academyof
Finland
Universities
Ministry ofTrade andIndustry
SitraFinnvera Oyj
Finpro
PARLIAMENT
GOVERNMENT
VTT
Tekes
Science andTechnology
PolicyCouncil
RegionalTE-Centres
Otherministriesand theirinstitutes
Ministryof
Education
Tekes’ mission statement
Tekes’ primary objective is to promote thecompetitiveness of Finnish industry and
the service sector by technological means.
Activities aim to diversify production structures,increase production and exports, and create a
foundation for employment and societal well-being.
DM 3218904-2003 Copyright © Tekes
Tekes core activities
Selective project funding
Technology programmes
DM 3218911-2003 Copyright © Tekes
Development of the innovationenvironment
Activation for innovation
Regionaltechnologicalcooperation
and promotionof regional
success
Internationaltechnologicalcooperation
andinternationalexpansion ofcompanies
0
50
100
150
200
250
300
350
400
450
500
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
349
386
316
252 244
386 395415
390 379
Tekes technology funding in the state budget
Million euros
DM 2604711-2003 Copyright © Tekes
National share of EU Structural FundsIndustrial R&D loansCapital loans for R&DIndustrial R&D grantsCoordination of programmesResearch funding
During the years 2000-2004 Tekes also had an annual allocation of 5-10 million euros from the EU Structural Funds as the EU share.
The funding resources for industrial R&D loans and capital loans for R&D merged in 2004.
Tekes Overseas Offices
DM 2604704-2004 Copyright © Tekes
Helsinki
Brussels
San JoseWashington, D.C.
Tokyo
Beijing
Technology Units at the TE-Centres
DM 2604704-2004 Copyright © Tekes
Technology units at the Employment and Economic Development Centres (TE-Centres) offer Tekes' services to companies and research units.
Technology units at the Employment and Economic Development Centres (TE-Centres) offer Tekes' services to companies and research units.
Lapland
Oulu
Kajaani
SeinäjokiKuopio
JyväskyläJoensuu
MikkeliTampere
PoriLappeenranta
Turku Tekes, Helsinki
Vaasa
Lahti
Information andcommunications technology
115 million euros
Other funding4 million euros
Total Tekes R&D funding in 2003by field of technology
Space activities18 million euros
Bio- and chemicaltechnology107 million euros
Product andproduction technology74 million euros
Energy, environment andconstruction technologies
74 million euros
DM 8098301-2004 Copyright © Tekes
Total 392 million euros and2,196 projects
Total 392 million euros and2,196 projects
Total funding 162 million euros and801 projects
Total funding 162 million euros and801 projects
VTT 36 million euros
Participation feesfor ESA programmes, 13 million euros
Other research funding8 million euros
Universities102 million euros
Tekes research fundingin 2003
Other research institutes3 million euros
In many research projects there are participantsfrom several universities or research institutes.
DM 8098301-2004 Copyright © Tekes
Technology programme model
Steering groupenterprises
TekesGrants
Company R&D projects
Research projects of research institutes and universities
SynergyNetworking
Part financing
preparationcoordinationdecision
making
DM 3025602-2004 Copyright © Tekes
GrantsLoans
Capital loans
Pictures: © ESA, Okmetic, Stora Enso
Picture: © Elcotec
Bio- and Chemical Technology
DM 3025602-2004 Copyright © Tekes
Technology programmes in 2004
2000-2004
2001-2004
2001-2004
2001-2006
2003-2006
2003-2007
20
42
87
110
21
26
18
33
10
11
2
23
27
56
50
34
5
18
Process Integration *
Innovation in Foods
NeoBio - Novel Biotechnology *
Drug 2000 **
Wood Material Science
COMBIO - Commercialisation of Biomaterials
= Intertechnological programme = In cooperation with the Academy of Finland
***
Totalbudget
mill. euros
Participatingresearch
unitscompa-
nies
DM 6564009-2003 Copyright © Tekes
COMBIO - Commercialisation of Biomaterials
The goal of the COMBIO programme is to further develop the strong Finnish biomaterial technology
base in health care and to use business technologies to support the commercialisation of research results
The goal of the COMBIO programme is to further develop the strong Finnish biomaterial technology
base in health care and to use business technologies to support the commercialisation of research results
Time span: 2003-2007Extent: Approximately 26 million eurosResponsibility: Mika Sievi-Korte, Tekes
Aila Maijanen, TekesProgramme Manager: Heikki Laurila,
Frux Advisors Ltd.Further information: www.tekes.fi/ohjelmat/combio
How to enhance commercialisation of medical biomaterials research ?
focusing on market-driven opportunitiestraining of business skills, IPR and regulatory
issues long-term funding of research and R&D in key
technologiesincreasing the critical mass of research projectspromoting collaboration within Finlandpromoting the biomaterials field for vc’spromoting the internationalisation of Finnish
biomaterials companies
Background
The ageing population is the single most important reason for the rapid growth of the biomaterials sector in health care
The number of persons over 60 years is growing at a rate of 1.5 percent annually
the human body is “designed” to hold out for 30-40 years many tissues start to deteriorate at an increasing speed
after the age of 30 tissues can be repaired using biomaterials and by
combining tissue engineering and stem cell technology with biomaterials
Other sources of growth are new technologies in administering drugs and the evolutionary development of several surgical products that are implementing the use of biomaterials
DM 6564009-2003 Copyright © Tekes
Structure and Development
Globally, there are about 7,500 companies in the sectorTurnover is about 50 billion euros
an average of 6.5 million euros/company
The growth of different market segments varies between 8 and 40 percent annually
the average market growth of the pharmaceutical industry is 8 percent annually
Growth in the first half of 2003 was even more rapid than expected
there have been extensive mergers and acquisitions in 2003 because companies are seeking new technologies and distribution channels (M&A has not done away with overcapacity)
DM 6564009-2003 Copyright © Tekes
3-5 globally-acting companies in Finland in 2010Turnover 500 million euros (or even more)
the turnover from subcontractors has to be added to the above
80 percent of existing companies will disappear due to mergers and closures
even in the case of a closure, know-how will remain in Finland and is transferable to other companies
New companies with similar courses of development will constantly appear (80 percent will disappear)
DM 6564009-2003 Copyright © Tekes
Vision
Focus Areas
Materials and methods in tissue engineeringNew materials for drug delivery Implants
MAIN FOCUS: COMMERCIALISATION!
The programme focuses on three technology areasThe programme focuses on three technology areas
DM 6564009-2003 Copyright © Tekes
Material technologyBiomechanical modelling
Cell biologyStem cell research
Programme structure:
New materialsfor drug delivery
Multifunctionalimplants
Tissue engineering:bone
soft tissuecartilage
Company R&D Projects Company R&D Projects
Company R&D projects Company R&D projects
Themes for Public Projects
1. Biological materials and composites for artificial tissues
2. Bone tissue engineering from stem cells and scaffolds
3. Implants for tissue engineering
4. Release of drugs, structural studies and modelling 5. Biomaterials in ophthalmic surgery
6. Photopolymerisable gels
7. Implants based on memory metals
8. Multifunctional biomaterials
9. Biomechanically optimised multicomponent implants
10. Antimicrobial properties of bioactive glass and Si gel
11. Porous biodegradable or bioactive material
12. Optical fibre composite for medicine and dentistry
13. Bioactive resorbable composite for bone repair
DM 6564009-2003 Copyright © Tekes
State of the Programme
Participating research units 23
Participating companies 24
Projects underway 20 research projects 13 company projects 7
DM 6564009-2003 Copyright © Tekes
Conclusion:
Finland provides an excellent infrastructure for research and R&D on biomaterials and tissue engineering due to advanced
educational system public health care innovation and technology policy
proven process including basic reseach preclinical and clinical research product development process development full-scale manufacturing
Products taken from lab to market!
Thank You!